Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report-Reference-Cited by-同舟云学术

Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report

Published:2008-10-17 Issue:1 Volume:1 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

So Brian J,Bekaii-Saab Tanios,Bloomston Mark A,Patel Tushar

Abstract

Abstract Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

https://link.springer.com/content/pdf/10.1186/1756-8722-1-18.pdf

Reference5 articles.

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global Cancer Statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108.

2. Lopez PM, Villanueva A, Llovet JM: Systemic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials. Alimen Pharmacol Ther. 2006, 23: 1535-47. 10.1111/j.1365-2036.2006.02932.x.

3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, gane E, Bland JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med. 2008, 359: 178-90. 10.1056/NEJMoa0708857.

4. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: Bay 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64: 7099-109. 10.1158/0008-5472.CAN-04-1443.

5. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S: Sorafenib (BAY 43–9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007, 59: 561-74. 10.1007/s00280-006-0393-4.

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatocellular Carcinoma with Distant Metastasis Cured by 20-Day Sorafenib Treatment;Case Reports in Gastroenterology;2021-07-08

2. Long-term sustained complete response with off-therapy to sorafenib in advanced hepatocellular carcinoma: a case report;Kanzo;2020-05-01

3. Modern Outcomes Following Treatment of Hepatocellular Carcinoma in Hereditary Hemochromatosis;American Journal of Clinical Oncology;2019-08-20

4. Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell);Medicine;2018-10

5. Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?;memo - Magazine of European Medical Oncology;2018-08-24